CKChristian M. Korff

Christian M. Korff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christian M. Korff has a total of 389 co-authors. Here are the top co-authors by number of shared publications:

  • Emmanuelle Ranza

    Medigenome Swiss Institute of Genomic Medicine Geneva Switzerland

    4 shared publications
  • Margitta Seeck

    EEG and Epilepsy Unit, Department of Neurology, Geneva University Hospitals, Geneva, Switzerland

    4 shared publications
  • Alexey Koval

    Translational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland

    3 shared publications
  • Gaetan Lesca

    Department of Medical Genetics, University Hospital of Lyon, Claude Bernard University Lyon 1, Lyon, France

    3 shared publications
  • Gian Paolo Ramelli

    Pediatric Department of Southern Switzerland, San Giovanni Hospital, Bellinzona, Switzerland

    3 shared publications
  • Gonzalo P. Solis

    Translational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine University of Geneva Geneva Switzerland

    3 shared publications

Latest Publications

  • Open Access

    Comprehensive classification of HCN1 variants linked to neurodevelopmental disorders with and without epilepsy

    by Roberta Castelli, Carla Marini, Alessandro Porro, Anna Castellini, Greta Fontana, Andrea Saponaro, Gianpiero L. Cavalleri, Susanna Rizzi, Carlo Fusco, Amitav Parida, et al.

    Hyperpolarization-activated cyclic nucleotide-gated 1 (HCN1) channels mediate the cationic I h current, a fundamental regulator of neuronal excitability and synaptic integration, and are predominantly expressed in the cortex and hippocampus. Although HCN1 variants have been increasingly identified in patients with epilepsy, from milder forms to developmental and epileptic encephalopathies (DEE), genotype–phenotype correlations remain poorly defined. Here, we used patch-clamp electrophysiology and confocal imaging in HEK293 cells to functionally characterize 43 HCN1 variants identified in patients with neurodevelopmental disorders, with or without epilepsy. Based on biophysical properties, we established a classification system comprising four distinct functional classes: I) low or no current; II) hyperpolarizing shift in voltage dependence; III) depolarizing shift in voltage dependence; and IV) generation of an instantaneous current. The molecular basis for this classification was further interpreted using available cryo-EM structures of HCN1. Integration with clinical data from 50 patients revealed a striking correlation between functional class and clinical presentation. Loss-of-function variants prevailed among individuals with milder phenotypes or without epilepsy, with the latter distinctively clustering within the channel selectivity filter. In contrast, gain-of-function and mixed variants were predominantly associated with DEE. Finally, we demonstrate that allosteric modulators, including peptides NB6 and TRIP8b nano and the small molecule J&J12e, effectively normalize channel function across three of the four classes in vitro. These findings establish a biophysical framework for interpreting HCN1 variants, demonstrating that the direction of channel dysfunction is a major determinant of epilepsy risk and severity, and providing a conceptual foundation for future class-based precision medicine approaches.


  • Heterozygous RNF13 Truncating Variants Are Associated With Developmental and Epileptic Encephalopathy

    by Donald R. Latner, Susan M. Hiatt, Candice R. Finnila, Whitley V. Kelley, Marla Johnston, Jessica Patrick‐Esteve, Nour Elkhateeb, Mona A. Kamel, Tahsin Stefan Barakat, Marjon van Slegtenhorst, et al.

    Developmental and epileptic encephalopathy 73 (DEE73; OMIM 618379) is an autosomal dominant severe neurodevelopmental disorder associated with pathogenic variants in the RING finger protein 13 gene (RNF13; OMIM 609247), which encodes a transmembrane E3 ubiquitin ligase. The phenotype of affected individuals includes microcephaly, seizures, intellectual disability, developmental delay, absent or limited speech, restricted movement, cortical blindness, and skeletal defects (hip dysplasia, club feet, scoliosis). The currently known DEE73 phenotype is based on two reports of four unrelated individuals: three with missense variants in a di‐leucine motif that is essential for binding to the Adaptor Protein Complex 3 (AP‐3), and one with a truncating variant located in the last exon. This case series of an additional 13 affected individuals with RNF13 variants (2 missense, 11 truncating) supports and broadens previous reports. Importantly, it helps to define a narrow but critical region of the protein that is intolerant to truncating variation, although the gene is not highly constrained.

  • Open Access

    Altered structural connectivity in epilepsy with myoclonic atonic seizures

    by Polona Pozeg, Christian Korff, Joël Fluss, Solange Denervaud, Johanna Maeder, Patric Hagmann, Sébastien Lebon


  • Auswirkungen des Klimawandels in der Neuropädiatrie und Kinderpsychiatrie

    by Nora Hazan, Christian Korff, Dante Trojan

    Der Klimawandel erhöht Prävalenz und Schweregrad bestimmter neurologischer Störungen bei Kindern und wird damit weltweit zunehmend zum Gesundheitsproblem. Beispielsweise kann der Temperaturanstieg bei Hitzewellen die Manifestationen bestimmter Epilepsien direkt verschlimmern. Indirekt kann der Klimawandel zudem die Behandlung bestimmter chronischer neuropädiatrischer Erkrankungen erschweren. Besonders gefährdet sind Kinder in Situationen mit beeinträchtigtem Zugang zu Medikamenten und verschärften Ungleichheiten im Gesundheitsbereich, wie dies laut Berichten beispielsweise während der Winterstürme in Nordamerika der Fall ist. Auf der Grundlage des aktuellen Wissensstandes und von Fallstudien beleuchtet dieser Übersichtsartikel die Auswirkungen des Klimawandels auf Kinder mit neurologischen Störungen.

  • Impact du changement climatique en Neuropédiatrie et en Pédopsychiatrie

    by Nora Hazan, Christian Korff, Dante Trojan

    Le changement climatique augmente la prévalence et la sévérité de certains troubles neurologiques chez les enfants et est une préoccupation croissante pour la santé publique globale. L’augmentation des températures lors de vagues de chaleur, par exemple, peut directement exacerber les manifestations de certaines épilepsies. De manière indirecte, le changement climatique peut également contribuer à complexifier la gestion de certaines maladies neuropédiatriques chroniques. Les enfants sont particulièrement vulnérables lors de situations qui affectent l’accès aux médicaments et exacerbent les disparités en matière de santé, tel que cela a été rapporté lors de tempêtes hivernales en Amérique du Nord, par exemple. En intégrant l’état actuel des connaissances disponibles et des études de cas, cette revue souligne l’impact du changement climatique sur les enfants atteints de troubles neurologiques.

  • Case 25: Ictal [18F]FDG PET Imaging

    by Valentina Garibotto, Christian Korff, Maria Isabel Vargas, Serge Vulliemoz, Margitta Seeck

  • Open Access

    High-Density EEG Source Localisation of averaged interictal epileptic Discharges validated by surgical Outcome

    by Bernd J. Vorderwülbecke, Margherita Carboni, Sebastien Tourbier, Laurent Spinelli, Denis Brunet, Martin Seeber, Christian M. Korff, Shahan Momjian, Maria Vargas, Margitta Seeck, et al.

    Electroencephalographic source localisation (ESL) of interictal epileptiform discharges is a valuable tool for presurgical evaluation of pharmacoresistant focal epilepsy. Various forward models, inverse solutions algorithms, and software packages have been published. However, clinical validation studies are based on heterogenous end points and study cohorts. To allow comparison of different interictal ESL methods within one standardised dataset, we provide deidentified clinical data of 44 well-characterised patients with pharmacoresistant focal epilepsy and a first resective surgery, validated by 12-month postsurgical outcome. Thirty patients had favourable outcomes, including 28 with complete seizure freedom, indicating that the epileptogenic zone was correctly estimated. For each patient, pre-processed individual structural MRI, 257-channel EEG averages of homologous discharges, postsurgical structural neuroimaging, and detailed clinical and technical information are given. In patients with favourable outcomes, source maxima of averaged discharges were <10 mm remote from the resection in 67% and within a sublobe affected by the surgery in 83%. Future validation studies of new ESL approaches can be compared to this benchmark.


  • Open Access

    Novel Mutation at Cys225 in GNAO1‐Associated Developmental and Epileptic Encephalopathies: Clinical, Molecular, and Pharmacological Profiling of Case Studies

    by Yonika A. Larasati, Gonzalo P. Solis, Alexey Koval, Marie‐Céline François‐Heude, Julie Piarroux, Agathe Roubertie, Ruihan Yang, Ying Zhang, Dezhi Cao, Christian M. Korff, et al.

    GNAO1‐associated disorders have a large spectrum of neurological symptoms, from early‐onset developmental and epileptic encephalopathies (DEE) to late‐onset movement disorders. First reported in 2013 and now identified in around 400 cases worldwide, this disease is caused by dominant, mostly de novo missense mutations in GNAO1, the gene encoding the major neuronal G protein Gαo. Being the immediate transducer of a number of neuronal G protein‐coupled receptors, Gαo plays crucial functions in brain development and physiology. Here, we discover a novel mutation site in GNAO1, Cys225 mutated to Tyr or Arg in pediatric individuals from France and China (p.(Cys225Tyr) and p.(Cys225Arg), respectively), leading to severe early‐onset DEE. Molecular investigations characterize the novel pathogenic variants as deficient in the interactions with guanine nucleotides and physiological cellular partners of Gαo, with reduced stability and plasma membrane localization and a strong neomorphic interaction with the chaperone Ric8A. Salts of zinc, emerging as a promising targeted therapy for GNAO1‐associated disorders, impose a previously unseen effect on the mutant Gαo, accelerating the loss of its ability to interact with guanine nucleotides. Our study, combining clinical, cellular, molecular, and modeling approaches, describes deep insights into molecular etiology and treatment perspectives of the novel form of GNAO1‐associated disorders.


  • Comprehensive genetic diagnosis and therapeutic perspectives in 155 children with developmental and epileptic encephalopathy

    by R. van Heurck, E.B. Hammar, D. Ville, S. Lebon, N. Chatron, C. Marconi, B. Royer-Bertrand, G. Lesca, A. Superti-Furga, M. Abramowicz, et al.


  • Open Access

    A Personalized 14-3-3 Disease-Targeting Workflow Yields Repositioning Drug Candidates

    by Yonika A. Larasati, Gonzalo P. Solis, Alexey Koval, Christian Korff, Vladimir L. Katanaev

    Rare diseases typically evade the application of the standard drug discovery and development pipelines due to their understudied molecular etiology and the small market size. Herein, we report a rare disease-directed workflow that rapidly studies the molecular features of the disorder, establishes a high-throughput screening (HTS) platform, and conducts an HTS of thousands of approved drugs to identify and validate repositioning drug candidates. This study examines the pediatric neurological disorder caused by de novo mutations in YWHAG, the gene encoding the scaffolding protein 14-3-3γ, and the workflow discovers nuclear relocalization and a severe drop in 14-3-3γ binding to its phosphorylated protein partners as the key molecular features of the pathogenic hotspot YWHAG mutations. We further established a robust in vitro HTS platform and screened ca. 3000 approved drugs to identify the repositioning drug candidates that restore the deficient 14-3-3γ-phosphotarget interactions. Our workflow can be applied to other 14-3-3-related disorders and upscaled for many other rare diseases.